2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Imaging, Omics Technologies, Bioinformatics, Computational Biology, Profiling, Treatment Considerations, Combination Therapy, Drug Development, Biological Therapies, Checkpoint Inhibitor, Immunotherapy, Monoclonal Antibody Therapy, Non-Biological Therapies, Chemotherapy, Artificial Intelligence (AI), Machine Learning, Biological Processes, Pathogenesis, Genomics, Hematopoiesis, Immune Mechanism, Metabolism, Molecular Biology, Multi-Systemic Interactions, Diseases, Myeloid Malignancies, Chronic Myeloid Malignancies, Research, Fundamental Science, Translational Research, MPN, CML, CMML, Clinical Research, Clinical Trials, Study Population, Human, Adult, Elderly, Animal Model
PAPER

5501 Progressive loss of negative charge in the CALR C-terminus redefines the mechanism of CALR mutant myeloproliferative neoplasms and expands the spectrum of pathogenic CALR mutations

Nicole S. Arellano, MS, Shuyang Lin, BA2, Matthew Jenkins, PhD3, Ling Huang, MD4, Maihi Skeen, BS5, Will L Heaton, MS6, Callie Brown7, Saveg Yadav, PhD8, Marissa Trujillo9, Shane McCann10, Daniel Newell11, Nathan M. Krah, MD, PhD12, Joshua Siner, MD13, Aaron T. Gerds, MD, MS14, Angela Fleischman, MD, PhD15, Andrew Dunbar, MD16, Naveen Pemmaraju, MD17, Anthony D Pomicter, MS18, Ami B. Patel, MD19, Melissa Tjota, MD, PhD20, Peng Wang21, Anand Ashwin Patel, MD22, Jeetayu Biswas, MD, PhD23, Raajit K. Rampal, MD, PhD24, Anna Shestakova25, Sandro Pino-Ascencio, MD26, Harrison Tsai, MD, PhD27, Gabriela Soriano Hobbs, MD28, Ayda Soltanian, MD29, Samuel Benjamin Reynolds, MD30, Andrew T Kuykendall, MD31, Kevin Hicks32, Anton Rets33, Maggie Cox34, Stephen Oh, MD, PhD35, Shannon E Elf, PhD36
1 University of Utah, Salt Lake City, Utah, United States, University of Utah, Salt Lake City, Utah, United States
2 Washington University in St. Louis, St. Louis, Missouri, United States
3 University of Utah, Salt Lake City, Utah, United States
4 Washington University in St. Louis, St. Louis, Missouri, United States
5 University of Utah, Salt Lake City, Utah, United States
6 University of Utah, Salt Lake City, Utah, United States
7 University of Utah, Salt Lake City, Utah, United States
8 University of Utah, Salt Lake City, Utah, United States
9 University of Utah, Salt Lake City, Utah, United States
10 University of Utah, Salt Lake City, Utah, United States
11 University of Utah, Salt Lake City, Utah, United States
12 University of Utah, Salt Lake City, Utah, United States
13 Washington University in St. Louis, St. Louis, Missouri, United States
14 Cleveland Clinic and Case Comprehensive Cancer Center, Cleveland, Ohio, United States
15 University of California Irvine, Irvine, California, United States
16 MD Anderson Cancer Center, Houston, Texas, United States
17 MD Anderson Cancer Center, Houston, Texas, United States
18 University of Utah, Salt Lake City, Utah, United States
19 University of Utah, Salt Lake City, Utah, United States
20 University of Chicago, Chicago, Illinois, United States
21 University of Chicago, Chicago, Illinois, United States
22 University of Chicago, Chicago, Illinois, United States
23 Memorial Sloan Kettering Cancer Center, New York, New York, United States, Memorial Sloan Kettering Cancer Center, New York, New York, United States
24 Memorial Sloan Kettering Cancer Center, New York, New York, United States
25 University of Utah, Salt Lake City, Utah, United States
26 Brigham and Women's Hospital, Boston, Massachusetts, United States
27 Brigham and Women's Hospital, Boston, Massachusetts, United States
28 Brigham and Women's Hospital, Boston, Massachusetts, United States
29 University of South Florida, Tampa, Florida, United States
30 Moffitt Cancer Center, Tampa, Florida, United States, University of South Florida, Tampa, Florida, United States
31 Moffitt Cancer Center, Tampa, Florida, United States, University of South Florida, Tampa, Florida, United States
32 University of Utah, Salt Lake City, Utah, United States
33 University of Utah, Salt Lake City, Utah, United States
34 Washington University in St. Louis, St. Louis, Missouri, United States
35 Washington University in St. Louis, St. Louis, Missouri, United States
36 University of Utah, Salt Lake City, Utah, United States, University of Utah, Salt Lake City, Utah, United States

Canonical calreticulin (CALR) mutations in myeloproliferative neoplasms (MPNs) are heterozygous insertions/deletions that generate a +1 base pair frameshift (fs), replacing the negatively charged, Ca2+-binding C-terminus with a positively charged arginine/lysine-rich neopeptide. These mutations are classified as type 1 (52 base pair deletion) and type 2 (5 base pair insertion). Type 1 mutations remove more negatively charged C-terminal residues than type 2 and are associated with more aggressive disease and a substantially higher risk of myelofibrotic transformation. A decade ago, seminal studies demonstrated that the mutant neopeptide, shared by all pathogenic CALRfs mutations, is required for thrombopoietin receptor (MPL) binding and activation, JAK-STAT signaling, and cellular transformation. Consequently, acquisition of this mutant C-terminus has long been considered essential for CALR-mediated oncogenesis. 

We previously identified a patient with mild thrombocytosis harboring a novel in-frame CALR mutation (CALRdelEEED) that deletes four negatively charged Ca2+-binding residues (EEED) from the C-terminus without generating the canonical positively charged neopeptide. Functional characterization demonstrated that CALRdelEEED activates JAK-STAT signaling and induces an MPN phenotype in vivo, including expansion of atypical megakaryocytes in the bone marrow, thereby challenging the prevailing model that acquisition of the mutant neopeptide is required for CALR-mediated transformation (ASH 2025 Abstract #358).

To determine whether CALRdelEEED represents an isolated observation or a broader class of novel, pathogenic in-frame CALR variants, we surveyed CALR mutations in patients with hematologic disorders from ten centers across the United States and the UK Biobank. We identified several additional CALRdelEEED cases together with multiple recurrent in-frame CALR mutations deleting negatively charged Ca2+-binding residues. These variants clustered within residues E379-D408 of the CALR C-terminus, revealing a previously unrecognized mutational hotspot. Functional characterization demonstrated that each variant activated JAK-STAT signaling and conferred cytokine-independent growth to varying degrees, with signaling potency directly proportional to the extent of negative charge loss. Together, these findings establish that loss of negative charge within the CALR C-terminus may represent a clinically relevant mechanism of CALR-driven MPNs.

To define the molecular basis for this shared mechanism, we first asked whether CALRdelEEED, like canonical CALRfs mutants, binds MPL despite lacking the mutant C-terminus. Microscale thermophoresis measurements were consistent with binding between CALRdelEEED and MPL, albeit with lower affinity than canonical CALRfs mutants. These findings suggest that CALRdelEEED gains MPL-binding activity but interacts less effectively than CALRfs mutants, consistent with our previous finding that CALRdelEEED activates JAK-STAT signaling with lower potency than CALRfs mutants. To validate this interaction, we performed TurboID proximity labeling and chemical crosslinking, which demonstrated enhanced intracellular association of CALRdelEEED with MPL compared to wild type CALR.

Based on these findings, we next tested whether the electrostatic charge of the CALR C-terminus governs MPL activation, regardless of whether the neopeptide is present. Progressively increasing the electrostatic charge of the protein by replacing deleted aspartic and glutamic acid residues with positively charged arginines produced stepwise increases in MPL binding, JAK-STAT activation, and cytokine-independent growth. Conversely, progressively replacing arginines in the mutant C-terminus to aspartic acids abrogated these phenotypes.

Together, these findings redefine the molecular mechanism of mutant CALR by demonstrating that electrostatic remodeling of the CALR C-terminus, rather than acquisition of the mutant neopeptide itself, governs MPL activation and transforming capacity. Moreover, the extent of negative charge loss directly correlates with transforming activity, providing a mechanistic explanation for the greater pathogenicity of type 1 relative to type 2 CALRfs mutations. Finally, these findings establish that recurrent in-frame CALR variants previously classified as variants of unknown significance can alter CALR function and encourage consideration of expanded classification of pathogenic CALR mutations.

Nicole S. Arellano, MS: No relevant conflicts of interest to declare.